<?xml version='1.0' encoding='utf-8'?>
<document id="26058399"><sentence text="Drug-drug interactions that interfere with statin metabolism." /><sentence text="Lipid-lowering drugs, especially hydroxymethylglutaryl-CoA reductase inhibitors (statins), are widely used in the treatment and prevention of atherosclerotic diseases" /><sentence text=" The benefits of statins are well documented" /><sentence text=" However, myotoxic side effects, which can sometimes be severe, including myopathy or rhabdomyolysis, have been associated with the use of statins" /><sentence text=" In some cases, this toxicity is associated with pharmacokinetic alterations" /><sentence text=" Potent inhibitors of CYP 3A4 significantly increase plasma concentrations of the active forms of simvastatin, lovastatin and atorvastatin"><entity charOffset="98-109" id="DDI-PubMed.26058399.s6.e0" text="simvastatin" /><entity charOffset="111-121" id="DDI-PubMed.26058399.s6.e1" text="lovastatin" /><entity charOffset="126-138" id="DDI-PubMed.26058399.s6.e2" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.26058399.s6.e0" e2="DDI-PubMed.26058399.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26058399.s6.e0" e2="DDI-PubMed.26058399.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26058399.s6.e0" e2="DDI-PubMed.26058399.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26058399.s6.e1" e2="DDI-PubMed.26058399.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26058399.s6.e1" e2="DDI-PubMed.26058399.s6.e2" /></sentence><sentence text=" Fluvastatin is metabolized by CYP2C9, while pravastatin, rosuvastatin and pitavastatin are not susceptible to inhibition by any CYP"><entity charOffset="1-12" id="DDI-PubMed.26058399.s7.e0" text="Fluvastatin" /><entity charOffset="45-56" id="DDI-PubMed.26058399.s7.e1" text="pravastatin" /><entity charOffset="58-70" id="DDI-PubMed.26058399.s7.e2" text="rosuvastatin" /><entity charOffset="75-87" id="DDI-PubMed.26058399.s7.e3" text="pitavastatin" /><pair ddi="false" e1="DDI-PubMed.26058399.s7.e0" e2="DDI-PubMed.26058399.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26058399.s7.e0" e2="DDI-PubMed.26058399.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26058399.s7.e0" e2="DDI-PubMed.26058399.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26058399.s7.e0" e2="DDI-PubMed.26058399.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26058399.s7.e1" e2="DDI-PubMed.26058399.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26058399.s7.e1" e2="DDI-PubMed.26058399.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26058399.s7.e1" e2="DDI-PubMed.26058399.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26058399.s7.e2" e2="DDI-PubMed.26058399.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26058399.s7.e2" e2="DDI-PubMed.26058399.s7.e3" /></sentence><sentence text="" /><sentence text="This review discusses the pharmacokinetic aspects of the drug-drug interaction with statins and genetic polymorphisms in CYPs, which are involved in the metabolism of statins, and highlights the importance of establishing a system utilizing electronic medical information practically to avoid adverse drug reactions" /><sentence text="" /><sentence text="An understanding of the mechanisms underlying statin interactions will help to minimize drug interactions and develop statins that are less prone to adverse interactions" /><sentence text=" Quantitatively analyzed information for the low-density lipoprotein cholesterol lowering effects of statin based on electronic medical records may be useful for avoiding the adverse effect of statins"><entity charOffset="69-80" id="DDI-PubMed.26058399.s12.e0" text="cholesterol" /></sentence><sentence text="" /></document>